ArticleFrontiers in immunology2026
Dual-defense functionality of temporin-1LS from dark-spotted frogs (
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The escalating crisis of antibiotic resistance highlights the urgent need for novel antimicrobial agents. This study aims to identify and characterize temporin-1LS, a temporin-family antimicrobial peptide from the dark-spotted frog ( Methods: Structural and phylogenetic analyses were conducted to determine the peptide's conformation and evolutionary relationship. Expression levels of temporin-1LS in various tissues were assessed under basal and pathogen-challenged conditions using Result: Temporin-1LS possesses a conserved amphipathic α-helical structure and shows high phylogenetic homology with temporin-1GY. It was constitutively highly expressed in frog skin and significantly upregulated in the gut (47.4-fold) and liver (24.3-fold) following Discussion and conclusions: Temporin-1LS employs a dual-defense mechanism, combining direct antibacterial activity against susceptible pathogens with strategic enhancement of key macrophage functions to resolve infection. These findings position temporin-1LS as a promising scaffold for developing novel immunomodulatory anti-infectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.